Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ingenol mebutate - LEO Pharma

Next Previous
X
Search
Drug Profile

Ingenol mebutate - LEO Pharma

Alternative Names: 3-Ingenyl angelate; I3A; Ingenol-3-angelate; PEP-005; PEP005-015; Picato

Latest Information Update: 29 Apr 2020

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer LEO Pharma; Peplin
  • Class Antineoplastics; Ingenols; Macrocyclic compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Actinic keratosis
  • No development reported Basal cell cancer; Bladder cancer; Leukaemia; Squamous cell cancer; Warts

Most Recent Events

  • 11 Feb 2020 Discontinued - Registered for Actinic keratosis in European Union (Topical)
  • 11 Feb 2020 Withdrawn for Actinic keratosis in Iceland (Topical)
  • 11 Feb 2020 The European Commission withdrew the marketing authorisation of ingenol mebutate (Picato®) gel for the treatment of actinic keratosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top